Endothelin-1: a scientist's curiosity, or a real player in ischemic heart disease?

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Vascular Physiology

Background:

• Endothelin-1 is a potent vasoconstrictor peptide derived from endothelium.
• It has multiple biologic effects relevant to coronary atherosclerosis and ischemic heart disease.
• Elevated plasma endothelin-1 levels are observed in patients with coronary atherosclerosis, myocardial infarction, and angina.

Purpose of the Study:

• To review experimental and clinical data on endothelin-1's involvement in ischemic heart disease.
• To examine the effects of endothelin-1 blockade on experimental myocardial necrosis.
• To evaluate endothelin-1 blockade's impact on restenosis after percutaneous transluminal coronary angioplasty (PTCA).

Main Methods:

• Review of existing experimental and clinical data.
• Analysis of studies investigating endothelin-1's role in coronary vasoconstriction and ventricular fibrillation.
• Examination of research on endothelin receptor subtypes in the coronary vasculature.
• Evaluation of studies on endothelin-1 blockade in animal models.

Main Results:

• Exogenous endothelin-1 induces coronary vasoconstriction and can cause ventricular fibrillation in animals.
• Endothelin receptor subtypes are present and pharmacologically characterized in the coronary vascular bed.
• Increased plasma endothelin-1 levels correlate with coronary atherosclerosis and acute ischemic events.
• Endothelin-1 exhibits growth-promoting and mitogenic actions, implicated in restenosis post-PTCA.

Conclusions:

• Endothelin-1 is significantly implicated in the pathogenesis of ischemic heart disease.
• Endothelin-1 blockade demonstrates potential therapeutic benefits for myocardial necrosis and restenosis.
• Further research into endothelin-1 modulation is warranted for cardiovascular disease treatment.